Market Overview

UPDATE: Burril Initiates Sarepta Therapeutics at Market Outperform on Eteplirsen Potential

Structural Volatility Won't End For Several Years, Derivatives Strategist Says
Forbes: There Is 'A Bit' Of Hope For Sarepta Therapeutics
Recent Setbacks Have Duchenne Investors On Edge (Seeking Alpha)

Burril initiated coverage on Sarepta Therapeutics (NASDAQ: SRPT) with a Market Outperform rating and a $54 price target.

Burril commented, "Sarepta is currently in clinical trials evaluating Eteplirsen, a novel RNA splicing modulator poised to correct genetic mutations which result in a dysfunctional protein and cause diseases of large unmet need. To date, the company has demonstrated both safety and preliminary efficacy in Phase 1 and Phase 2 trials with patients amenable to Exon 51 therapy in Duchenne's Muscular Dystrophy (DMD). Given the final encouraging results from the 201/202 Phase 2 study, we believe shares are poised to move higher. If successful, we believe Sarepta's directed alternative splicing technology has the potential to revitalize the RNA therapeutics space and address multiple multi-billion dollar orphan disease markets."

Sarepta Therapeutics closed at $29.35 on Friday.

Latest Ratings for SRPT

Jan 2016RBC CapitalDowngradesOutperformSector Perform
Jan 2016Piper JaffrayDowngradesOverweightNeutral
Nov 2015Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: BurrilAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (SRPT)

Get Benzinga's Newsletters